{"groups":[{"description":"Nivolumab 3 mg/kg IV over 60 minutes Q2W","id":"FG000","title":"Nivolumab"},{"description":"Dacarbazine: 1000 mg/m\\^2 IV over 30 to 60 minutes Q3W, or Carboplatin: Area under the concentration-time curve (AUC) 6 IV over 30 minutes Q3W, and Paclitaxel: 175 mg/m\\^2 IV over 180 minutes Q3W","id":"FG001","title":"Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"13"}],"type":"Participant request to discontinue Study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"16"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Poor/Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Participant no longer met study criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"272"},{"groupId":"FG001","numSubjects":"133"}],"comment":"Started = Randomized","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"268"},{"groupId":"FG001","numSubjects":"102"}],"comment":"Completed = Received Treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"31"}],"type":"NOT COMPLETED"}],"title":"Pre-Treatment"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"192"},{"groupId":"FG001","numSubjects":"74"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"11"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"}],"type":"Adverse Event unrelated to Study Drug"},{"reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"7"}],"type":"Participant request to discontinue Study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"3"}],"type":"Maximum Clinical Benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Poor/Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Participant no longer met Study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"}],"type":"Other reasons"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"268"},{"groupId":"FG001","numSubjects":"102"}],"comment":"Started = Received treatment","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Completed = Completed treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"268"},{"groupId":"FG001","numSubjects":"102"}],"type":"NOT COMPLETED"}],"title":"Treatment"}],"preAssignmentDetails":"405 participants randomized and 370 treated."}